

## Polatuzumab vedotin powder for concentrate for solution for infusion (Polivy®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2524	In combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT).	Available in line with local or regional guidance	16/08/2023	18/10/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/polatuzumab-vedotin-polivy-reassessment-smc2524/">https://www.scottishmedicines.org.uk/medicines-advice/polatuzumab-vedotin-polivy-reassessment-smc2524/</a>				

## Azacitidine film-coated tablets (Onureg®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2533	Maintenance therapy in adult patients with acute myeloid leukaemia who achieved complete remission or complete remission with incomplete blood count recovery following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation.	Available in line with local or regional guidance	16/08/2023	18/10/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/azacitidine-oral-onureg-full-smc2533/">https://www.scottishmedicines.org.uk/medicines-advice/azacitidine-oral-onureg-full-smc2533/</a>				

<b>Selumetinib hard capsules (Koselugo®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2540	As monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.	Not routinely available as not recommended for use in NHS Scotland	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/selumetinib-koselugo-full-smc2540/">https://www.scottishmedicines.org.uk/medicines-advice/selumetinib-koselugo-full-smc2540/</a>				
<b>Tezepelumab solution for injection in pre-filled syringe (Tezspire®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2541	As an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.  SMC restriction: in adults and adolescents 12 years and older who either (i) experienced at least three exacerbations in the previous year and are not receiving maintenance treatment with oral corticosteroids or (ii) have blood eosinophils $\geq 150$ cells/microlitre and are receiving maintenance treatment with oral corticosteroids.	Available in line with local or regional guidance	16/08/2023	18/10/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/tezepelumab-tezspire-full-smc2541/">https://www.scottishmedicines.org.uk/medicines-advice/tezepelumab-tezspire-full-smc2541/</a>				

Avalglucosidase alfa 100mg powder for concentrate for solution for infusion (Nexviadyme®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2546	Long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid $\alpha$ -glucosidase deficiency).	Available in line with national guidance	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/avalglucosidase-alfa-nexviadyme-abb-smc2546/">https://www.scottishmedicines.org.uk/medicines-advice/avalglucosidase-alfa-nexviadyme-abb-smc2546/</a>				
Ropeginterferon alfa-2b solution for injection in pre-filled pen (Besremi®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2563	As monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	Not routinely available as not recommended for use in NHS Scotland	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/ropeginterferon-alfa-2b-besremi-resubmission-smc2563/">https://www.scottishmedicines.org.uk/medicines-advice/ropeginterferon-alfa-2b-besremi-resubmission-smc2563/</a>				

<b>Baricitinib film-coated tablets (Olumiant®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2572	For the treatment of severe alopecia areata in adult patients.	Not routinely available as not recommended for use in NHS Scotland	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/baricitinib-olumiant-full-smc2572/">https://www.scottishmedicines.org.uk/medicines-advice/baricitinib-olumiant-full-smc2572/</a>				
<b>Dapagliflozin film-coated tablets (Forxiga®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2577	In adults for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) >40%.	Not routinely available as there is a local preference for alternative medicines	16/08/2023	30/11/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/dapagliflozin-forxiga-abb-smc2577/">https://www.scottishmedicines.org.uk/medicines-advice/dapagliflozin-forxiga-abb-smc2577/</a>				

Apalutamide 60mg film-coated tablets (Erleada®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2579	In adults for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	16/08/2023	31/10/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/apalutamide-erleada-abbreviated-smc2579/">https://www.scottishmedicines.org.uk/medicines-advice/apalutamide-erleada-abbreviated-smc2579/</a>				
Belumosudil film-coated tablet (Rezurock®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2583	Treatment of patients aged 12 years and older with chronic graft-versus-host disease (chronic GvHD) who have received at least two prior lines of systemic therapy.	Available in line with national guidance	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/belumosedil-rezurock-uo-smc2583/">https://www.scottishmedicines.org.uk/medicines-advice/belumosedil-rezurock-uo-smc2583/</a>				

Icosapent ethyl soft capsules (Vazkepa®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2602	<p>To reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (<math>\geq 1.7</math>mmol/L) and</p> <ul style="list-style-type: none"> <li>• established cardiovascular disease, or</li> <li>• diabetes, and at least one other cardiovascular risk factor.</li> </ul> <p>SMC restriction: use as secondary prevention in patients treated with a stable dose of statins, low-density lipoprotein (LDL) cholesterol levels <math>&gt; 1.04</math>mmol/L and <math>\leq 2.60</math>mmol/L, raised fasting triglycerides (<math>\geq 1.7</math>mmol/L) and with established cardiovascular disease defined as a history of any of the following:</p> <ul style="list-style-type: none"> <li>- Acute coronary syndrome (ACS) (such as myocardial infarction (MI) or unstable angina needing hospitalisation)</li> <li>- Coronary or other arterial revascularisation procedures</li> <li>- Coronary heart disease</li> <li>- Ischaemic stroke</li> <li>- Peripheral arterial disease</li> </ul>	Not routinely available as there is a local preference for alternative medicines	16/08/2023	20/12/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/icosapent-ethyl-vazkepa-ft-resub-smc2602/">https://www.scottishmedicines.org.uk/medicines-advice/icosapent-ethyl-vazkepa-ft-resub-smc2602/</a>				

## Aflibercept solution for injection in pre-filled syringe (Eylea®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2612	In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.	Not routinely available as not recommended for use in NHS Scotland	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/aflibercept-eylea-non-sub-smc2612/">https://www.scottishmedicines.org.uk/medicines-advice/aflibercept-eylea-non-sub-smc2612/</a>				

Dermatophagoides pteronyssinus and Dermatophagoides farinae oral lyophilisate (Acarizax®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2613	<p>Adult patients (18-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:</p> <ul style="list-style-type: none"> <li>- persistent moderate to severe house dust mite allergic rhinitis despite use of symptom relieving medication</li> <li>- house dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.</li> </ul> <p>Adolescents (12-17 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.</p>	Not routinely available as not recommended for use in NHS Scotland	16/08/2023	16/08/2023
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/medicines-advice/dermatophagoides-pteronyssinus-and-dermatophagoides-farinae-acarizax-non-sub-smc2613/">https://www.scottishmedicines.org.uk/medicines-advice/dermatophagoides-pteronyssinus-and-dermatophagoides-farinae-acarizax-non-sub-smc2613/</a>				